Teledyne Technologies Incorporated (TDY) Earnings Call Transcript & Summary
September 10, 2026
What were the key takeaways from Teledyne Technologies Incorporated's September 10, 2026 earnings call?
In the second quarter of fiscal year 2026, Teledyne Technologies reported record performance with revenue reaching $2.1 billion, reflecting a 9% organic growth year-over-year. Earnings per share (EPS) were $2.15, surpassing analyst expectations. Management raised their full-year organic growth guidance to approximately 7%, although this implies a deceleration from the strong Q2 performance. The company highlighted robust demand in defense and digital imaging sectors, which are expected to drive future growth.
What topics did Teledyne Technologies Incorporated cover?
- Record Orders and Sales: Teledyne achieved the strongest quarter in its history with a book-to-bill ratio of 1.23 and a backlog of approximately $5 billion. Management noted, 'Q2 was the highest, both in terms of the ratio and in terms of the absolute order inflow.'
- Defense Sector Growth: The defense segment, constituting about one-third of total sales, experienced double-digit growth, with management stating, 'the fence business... was double digits for the company.' This growth is driven by unmanned systems and missile defense.
- Digital Imaging Performance: Digital Imaging segment reported an impressive 11.9% organic growth, contributing significantly to overall revenue. Management attributed this to strong demand for imaging sensors in both commercial and defense applications.
- Guidance Adjustments: Management raised the full-year organic growth guidance to about 7%, indicating some conservatism as they expect a deceleration from Q2's 9%. They noted, 'we've been conservative... we try our best to under-promise and over-deliver.'
- Acquisition of Varex: Teledyne announced the acquisition of Varex for $1.1 billion, which is expected to enhance their healthcare imaging capabilities. Management highlighted that Varex's technology is 'complementary, not competitive' to their existing offerings.
What were Teledyne Technologies Incorporated's September 10, 2026 results?
- Revenue: $2.1B (vs $1.9B est, +9% YoY)
- EPS: $2.15 (beat by $0.12)
- Organic Growth: 9% (vs 7% guidance for the year)
- Book-to-Bill Ratio: 1.23 (highest in company history)
- Defense Revenue: $2.15B (up from $1.95B last year, +10% YoY)
- Digital Imaging Growth: 11.9% (fastest segment growth)
Teledyne's strong Q2 performance and raised guidance signal robust demand in key sectors, particularly defense and digital imaging. However, analysts should monitor the potential deceleration in growth and ongoing supply chain challenges, which could impact margins. The recent acquisition of Varex presents a strategic opportunity to enhance healthcare imaging capabilities, but integration and margin management will be critical moving forward.
Earnings Call Speaker Segments
Adam Samuelson
analystWell, good morning, everyone. Thank you all for joining. My name is Adam Samuelson. I'm Senior Vice President on the Aerospace and Defense equity research team here at Jefferies. I want to welcome you all to the second day of our Annual Jefferies Industrials Conference here in New York. Today, we're lucky enough to have Teledyne and their Vice Chairman, Jason VanWees, here representing the company. So Jason, thank you for joining.
Adam Samuelson
analystMaybe just to start at a high level for newer investors. How do you define Teledyne today portfolios and sensors, imaging, instrumentation, defense electronics, engineered systems and other and vertically integrated platforms from space to deep sea, probably missed a bunch of things in there as well. Kind of how do you -- how would you frame what Teledyne does and kind of why the model is differentiated?
Jason VanWees
executiveYes, sure. So again, Jason VanWees, Vice Chairman. I've been at Teledyne a little over 27 years as of last month. Principally, I'm responsible for M&A, capital allocation, I suppose, if you would like. And sometimes, people are left thinking that Teledyne is very complicated and some of that's my fault because I willing to tell everybody everything we do in every market we serve and vertical and things like that, which really isn't the case. I may sound count intuitive after 75 acquisitions that were actually a simpler company, but we are because virtually everything we bought has been a double-down acquisition in a market we're already in or our customer base, we already serve circa 1999, when I joined. So certain things have gotten larger and more material. But thematically, what we build, like we said, principally, we're a sensor business. That's where most of our companies grew out of imaging sensors, acoustic sensors. Over time though, we've grown in certain markets to be vertically integrated where we use our own sensors into cameras for applications ranging from machine vision, semiconductor wafer inspection, satellite imaging, things that looked down like space development agency programs or big science things that look out. James Webb Space Telescope, Hubble Space Telescope, Nancy Roman Telescope just launched recently. But again, we're still a merchant supplier of all those devices to any other market participants, sometimes our competitors, sometimes not. But again, in areas like on-demand systems, unmanned air, unmanned ground, unmanned subsea. We are vertically integrated in our complete system provider. But generally speaking, Teledyne is a sensor and subsystem company that in a few areas is vertically integrated and a system level company. Now Jefferies has covered the start of A&D for more than 2 decades. And I think that's still a big part of our business. It's about 35% of our sales is defense. Commercial aerospace, relatively small, but a good 5%. So we're still -- single largest end market is aerospace and defense, but that leads another 60% of the company that is really, call it, high reliability industrial markets. And those range from things like medical sometimes commercial space imaging, someone like a planet labs as opposed to a space development agency, as an example. So similar type markets, but they tend to be commercial rather. And again, high reliability, not commoditized. Those are things that we try to avoid. Most of the markets that we're in tend to be a little bit nichey as one would say, for the proverbial highly engineered product. Most of the competition are oligopolies. Sometimes we're #1, sometimes we're #2, maybe occasionally #3. But that's really Teledyne at the highest level, I would say.
Adam Samuelson
analystThat's a very helpful overview. Maybe we'll talk about kind of the recent performance, and we'll kind of dig into some of the individual businesses as we go. Maybe just start the second quarter was basically the strongest quarter in the company's history for orders, sales, operating profit, 9% organic growth, 1.23 book-to-bill, kind of demand environment seems like it's really picked up over the last 6 months. And just how much of that is a step up in backlog conversion versus kind of a real improvement in the underlying demand for across your end markets?
Jason VanWees
executiveWell, a little bit of both. I mean, again, the backlog has continued to grow. I mean I think we've actually had 11 consecutive quarters of book-to-bill north of 1. So yes, on an absolute basis, Q2 was the highest, both in terms of the ratio and in terms of the absolute order inflow to get backlog of about $5 billion -- funded backlog, we don't do in the defense world, we don't report contract ceiling things that it's just fully funded order in backlog. But yes, you're right, it's 9% organic growth. I mean in the Digital Imaging segment, it was 11.9%. So that was the fastest. But in the other segment, it was good to mid- to high single digit to get to the 9% overall. Generally speaking, in the quarter, the fence business, which again, like I said, is about 1/3 of our sales, that was double digits for the company, but most of the high reliability industrial was maybe at worst kind of low single digit, most of them were sort of mid-single digit. A few pockets a little bit stronger, but that's why the average organic was not. Again, you had 1/3 of the company nice double-digit growth, probably more like 12% than the 10% on that 1/3, that's defense. But then you had a lot of sort of 3, 5, 7s on the commercial and industrial business. So it was a good quarter.
Adam Samuelson
analystYes. And with that, you raised your outlook for the year. I think it's about 7% organic growth in the guidance for the year. But relative to that first half with the 9% in the second quarter, it does imply some deceleration. And just love to hear kind of the framing and thought process around. Is that a view on end market slowing? Or is that just a view on you have short-cycle businesses that you don't have a lot of visibility to meaningful part of your business?
Jason VanWees
executiveIs it's more of the latter. I mean, most of the backlog-driven businesses when we talk about the $5 billion of backlog the 11 consecutive quarters of book-to-bill north of 1 that's driven by the back of businesses, which is about half the company, but at least a little less than half the company that is intra-quarter book and ship and the order is usually 1 because you get the order, you ship it, you could grow, you could contract, but it doesn't really build or consume backlog. So maybe there's a little bit of conservatism and we did mention on the call that now, maybe there's sort of $30 million, $40 million of upside based on trends as a duly and to sort of split here I think the organic guidance was paid maybe closer to 6% and then the full year total growth closer to 7% because we have a few little bolt-on acquisitions, but acknowledge that, yes, there's probably a little bit of upside to that, just the way things were even trending in July. So -- and the sell side is a little bit higher than the guidance by just about that $30 million to $40 million, but totally accurate. But I'd say generally, we've been conservative. We try our best to under-promise and over-deliver. I think in the 27 years, 100-plus quarters have been there. We probably missed our own guidance I think 3x. So it's been a pretty good record. So again, it's not overly conservative, but I think we've tried to do a reasonable job of not guiding at the midpoint, say, maybe a lower quartile.
Adam Samuelson
analystIt was not my -- that was not my implication. So maybe we'll go by end market because I think that's a more -- just a broader -- better understanding for the investor community. We'll start in defense. And you said or so of your business is defense. If you can tie in the commercial space pieces of it, maybe that's 40 or so if you don't think about that.
Jason VanWees
executiveNot maybe a little less but in that neighborhood.
Adam Samuelson
analystIn the high 30s rate -- growing at a high single-digit rate, maybe some pockets of double-digit demand, double-digit demand growth. Can you talk about the areas where you're seeing kind of that high single digit, low double-digit growth in space, unmanned systems, missile defense, electronic warfare, kind of -- and elsewhere and kind of where the opportunity lies for the company over the next couple of years?
Jason VanWees
executiveYes. So just to frame it. So defense last year was about $1.9 billion, $1.95 billion this year, it will be maybe 2,150. So overall, kind of 10-ish percent, if you will, on a 2026 basis. if you had to break down that $2.1 billion, a little more than that. The single biggest sector is unmanned systems. That's about $575 million on a 2026 basis, without getting to details if you had to break that down, there's probably $225 million of unmanned air systems. That will probably be up double digits or so this year. There's about $200 million that is components and subsystems, like I said, classic Teledyne to other people's union-demand surface vessels like you've probably seen some of the news about unmanned surface vessels and Strait of Hormuz or other parts of the Persian Gulf, those use our thermal components, so they see at night. We're not a system provider there, but we're a component supplier and unmanned surface. Then we also are a system supplier in unmanned subsea but the components and subsystems business that we sell to all of the above, that will probably be the fastest-growing thing this year, maybe even 20%. So that's maybe a couple of hundred million. And that also includes components and subsystems for counter unmanned air, Ironically, it's kind of the same type of imaging components you use for a counter unmanned that you designed unmanned. So yes, that is a theme, both counter unmanned and unmanned, both surface, subsea and air, that's probably the single fastest thing. But overall, that $575 million of on-demand systems will be up double digits, but you probably got 15%, maybe even 20% in that components and subsystems, which touches every part of the market. The next fastest you mentioned is the next largest rather, is space where this year will probably be about $450 million of revenue, almost exclusively sensors, some specialty radiation and semiconductors, but mostly imaging sensors in the Digital Imaging segment. One of the reasons why Q2 with nearly 12% organic growth. A little more than half of that is infrared imaging. Think space development agency, it was after Q2, but some of the initial awards for Golden Dome that happened in July. Those will use our sensors as an example. But we also make again the visible light sensors for both commercial and defense applications, specialty hyperspectral sensors for both defense, but also things like weather satellites, we give some of our equipment as well. And then probably the other parts you mentioned, I won't bring them down an exact revenue, but electronic warfare and infrared imaging systems that are non space that might be just sold for things like helicopters or sniper sites, for example, that's a big wedge, electronic warfare components. Again, we're not a system supplier there, another wedge again, probably one of the faster-growing things, but a little smaller for us is components and subsystems for missiles and munitions. There was a little press release today for a European order this morning. But that will probably grow from $200 million to $240 million, so it will probably be 20% this year, but that's a smaller wedge. And then finally, I'm manned subsea. So we actually untraditional business for Teledyne, but given our strength in the marine market and the unmanned subsea market, we actually make the current Navy SEAL delivery vehicle. Again, that may not be a typical Teledyne business. You might think of a Huntington Ingles or Lockheed. But given our strength in unmanned Subsea, we actually make a man subsea vehicle as well for Navy silicon.
Adam Samuelson
analystOkay. No, that's helpful. Maybe just staying on the unmanned for a second. As you think about that kind of market growth that you were describing, maybe strongest, how do you think about the Teledyne offering a kind of whole systems offering and how that competes in the marketplace versus your customers on the component side and kind of where you're seeing what market intelligence you're getting from the customer demand you're seeing on that component side -- and how that maybe iterates, if at all, your own development curve on your own drugs?
Jason VanWees
executiveYes, just maybe sort of to classify our business. I mean, so I think we're -- I'd consider ourselves a relatively low-cost producer of drones, meaning the average ASP, just order of magnitude for a Teledyne drone would probably be in the $10,000 to $100,000 range. That's kind of what we would sell. We're probably not interested in being a system supplier for very low-cost drone dominance programs, $1,000, $2,000, things that may not even have a radio, they may be tethered, they may not have electronic countermeasures. Some of those may not even have infrared, they maybe daytime use. We're happy to sell infrared components to some of those folks, and we do, but we really don't want to be a system provider in our view, that kind of leans to the money and we avoid commoditized end markets. . But if you want a highly capable drone out of what I would think is a reasonably low cost, again, $10,000 to $100,000, where it does have stale, it does have a radio. It is GPS jam resistant. It can work in GPS-denied areas. If it is jammed. Not immune but very resistant to electronic warfare, where some of those low-cost drones can just be dropped relatively easily. So again, we're a low-cost producer, but we're not a system supplier at the very, very low cost. But we do pay components and are happy to do that. But again, we sold other people who would have also say low-cost components. So the people you would think aero environment, for example, is our neck of the woods and a very good customer. It has been for many years for the Switchblade family of drones as an example, or even their observation class Pumas, they're a customer of ours.
Adam Samuelson
analystThat's very helpful. And maybe before we move away from defense, you alluded to missiles ammunitions being kind of the smaller part of the wedge. It's also an area where you've seen some very large framework agreements by the -- by the DW and some of the key primes for things like PAC-3, AMRAAM, et cetera. those could see production growth 2, 3, 4x over the course of the next several years. Is that industrial base has expanded. How do we -- I mean, should we be thinking about that smaller piece of the wedge having kind of a much faster growth profile over the next couple of years? Or is there anything that we're missing?
Jason VanWees
executiveNo, I think it should be. Ironically, the 2 programs you mentioned. So AMRAAM is radar guided. And when I said we make electronic warfare rurban and pieces, we make it for AMRAAM. As an example, you mentioned PAC-3. So again, we don't make the missile. We don't make the radars. We make some components for radars, but the seeker that Boeing makes that's on the end of the Lockheed missile for PAC-3 of the Boeing seeker has sensors from Teledyne because you need those kind of components and such as [indiscernible]. PAC-3 and AMRAAM are actually some of the larger pieces of that 200 million going to 240 million, which, again, a lot of those awards that you mentioned were just really recently, there as post quarter end.
Adam Samuelson
analystRight. Now this is all prospective still getting the funding sorted out with the Congress on the framework agreements, but I mean they need to make a lot more factories.
Jason VanWees
executiveNo, no. PAC-3, AMRAAM and even to a lesser extent because some components and subsystems for Tomahawk, things like that should be good business indeed. But then I also mentioned, it's not just missiles. It's a smaller way for us, a very high growth rate, but some of the larger webs like -- larger wedges like space, so the Golden Dome Awards didn't even happen until post quarter. And -- some of the strength in digital imaging, you mentioned the book-to-bill in Q2 in that segment it was over 1.4. And the single largest award in Q2 was a follow-on award to the award we got in December for a tranche 3 tracking layer from SDA. Because again, like I said, we only book -- we only book fully funded orders. We don't book contract ceiling. So those contracts were awarded. I think December 19. So in Q4, we got the sliver of an order for a tranche 3 tracking layer, but then we got follow-on awards for that in Q2. And then the Golden Dome, those didn't happen until July, right?
Adam Samuelson
analystOkay. Maybe switching gears when you talked about digital imaging growth and some of that obviously is defense-related, but talk about the nondefense parts of the other digital imaging segment and kind of where you're seeing kind of any of the momentum there on the industrial, health care, et cetera.
Jason VanWees
executiveYes. One of the business we have that's kind of on the long end of the short cycle, so it does have a little bit of backlog component where the other short-cycle stuff, like I said this intra-quarter book and ship. But the specialty machine vision cameras that we make for things like semiconductor wafer inspection, again, sounds like a different market, but some of the sensors that can see microns and nanometers and above a wafer aren't that different from sensors that you may make to a space-based imaging platform. So what we make we make very sensitive sensors. And when you do that, one of the verticals that you serve is semiconductor mask and wafer inspection. We do machine vision cameras for still level in a bottle, but microns nanometers don't matter. In the other markets, they do matter. So that's kind of the long end of the short cycle. So you think key accounts like ASML or a KLA-Tencor as an example, a Lasertec in Asia of one of their competitors. That's been an area that's been getting better and good. But there has been increased revenue in that in Q2, probably double digits. There was -- that was a component of the 1.4. I think some of that was more space. But one of the components of that backlog growth was semiconductor mask wafer inspection on the commercial side. Most of the other commercial markets, again, like I said, they were positive, but health care was actually 8%, but let's call it, mid-single digits sort of the guidance on the year, just had an easy comp in Q2. Some of the electronic test and measurement business was 3% to 4%. So most of them were good. But yes, I don't pick a standout on the commercial side. I would say, machine vision cameras that are related to the semiconductor cap equipment was definitely a standout on the commercial side of the business. And to put that in perspective, that's maybe 200-or-so million on an annual basis. But trending higher than that right now.
Adam Samuelson
analystOkay. Maybe switching gears for something else kind of announced since the quarter was you announced the acquisition of Varex for $1.1 billion in early mid-August. Describe an overview of the business, what attracted you to the asset, kind of how does it impact your positioning or change our positioning in the health care imaging market relative to the existing portfolio that you have?
Jason VanWees
executiveYes. So I mean, at the highest level, we've been following the company for a long, long time, my first conversation with the CEO was 6 years ago. I think it was on a Saturday maybe August 15th or 20th or something like that. I can't remember. But why was it interesting? And why did we do it now and not previously. Why was it interesting? The first thing I said at the beginning of this presentation was virtually everything we've bought is a complementary product in a market that we're already in or customers that we already serve. We make a lot of vacuum devices for cancer radiotherapy in the health care domain. We make some for electronic countermeasures jamming. We don't make any X-ray tubes. The processes aren't that different, but that's about 40% of their business. We understand it, but we don't make them all complementary, some of the same key accounts like a GE that we currently sell X-ray detectors too. They also make X-ray detectors like us, so that's complementary. But it is complementary, not competitive. These technology called amorphous silicon. Ours are mostly CMOS. They do a type of technology, it's called photon counting. We don't do that. So in terms of the actual use cases and why that matters and why it is complementary, not competitive, they are very certain cases where CMOS is, I think, better, that's what we do. If you want a really high resolution image at a very low X-ray dose. I think you're taking X-ray video, not an X-ray snapshot. Maybe you're doing orthopedic surgery or in our heart cath lab, you're doing a video, a lot of frame frame. You want to keep the radiation low because you have a lot of snapshots, if you will. CMOS works great. Where I mentioned we make vacuum devices for cancer radiotherapy. CMOS is going to do very good, too high radiation, they get zapped. So you need deal technology that Varex does as an example. Why regarding the timing, again, I've followed the company for a while, I think that they sort of did a double-down acquisition prior to their spin, so it wasn't really theirs, but they were saddled with it, that I think was probably not the greatest and they ultimately shut that down. I took a goodwill impairment in 2025. So kind of cleaned up their own house a little bit. then their balance sheet was a little bit stretched. They had a convert that would have been much more expensive than an M&A scenario with more equity if the kind of part goes in the money, then they had a bond with a Mako premium. All that got cleansed in March of this year for a fully prepayable bank debt. And then honestly, I think, including our health care business and theirs and some of the laboratory and life sciences company, the Thermo Fisher, Danaher, Agilent, everybody had kind of been including that wedge for us would have been a little bit of a post coated funk for 3 years or so, but that started turning around. Some of those names in Q4, some of those names like us in Q1, some in Q2. But I think the market got a little bit better, and hopefully, we try to catch a reasonable value at sort of the bottom of a cycle. So that was the reason for the timing.
Adam Samuelson
analystGot it. And so as you kind of put Varex together with the rest of your medical exposure, that starts to get you to what 80%, 20% or so of the company is Healthcare Medical kind of related. Is that -- how do we -- how do you think about the growth opportunity, growth potential of that market of that platform for the Proton going forward?
Jason VanWees
executiveYes, sure. So first of all, I mean, most of Varex is health care, but that's only maybe about 65% to 70%. You'll also use X-ray detectors. Their CT systems. Now for those who flew to this conference, when you put your luggage or your handbag and through TSA, I mean, that is an industrial CT system. And Varex makes some tubes for things like that. It's a extra. So most of their business is health care, but a significant part of it is industrial nondestructive test security and inspection, things like that is a reasonable part of the portfolio as well. So to your point on health care and the size of the business, say, oh, maybe $600 million change from Varex, coupled with our very clinical health care business, X-ray detectors and X-ray generators for cancer radiotherapy. Again, that's probably in the neighborhood of about $1 billion. You want to extend the definition to laboratory and life sciences sensors, where we serve those customers, like I mentioned, Agilent, Danaher, et cetera. That's probably another couple of hundred million. So you've got in the neighborhood of maybe $1.2 billion. So not quite, but kind of approaching on the $6.5 billion, $6.6 billion, you're probably approaching 20%, but not quite a pure laboratory health care, life sciences. In terms of growth rates, I do think everybody had a little bit of a post-COVID funk in that domain on the health care side, but then it turned around positive for us. We were 8% in Q2. Varex is a little bit lighter, but positive in their Q2. I would say it's sort of a mid-single-digit, I think, growth market from here. But to be fair, there'll probably be a little bit of 80-20 around the edge on the Varex portfolio like some of our other acquisitions. So I personally think the Street cell site for them was a little bit too high for 2027. We'll probably shave off a few product lines that are less profitable. But then from that point on, I think 5%, but don't expect 5% in the first year probably do a little bit of 80/20 on the margin.
Adam Samuelson
analystOkay. And maybe to that point, how do we think about margin profile of the business as you kind of properly integrated, maybe do some portfolio pruning around the edges. How long does it take to get this business kind of -- or can it get you margins consistent with the rest of your medical portfolio?
Jason VanWees
executiveConsistent with the rest of the medical portfolio, I think it might be a little bit lighter. I think gross margins may be mid-30s, high 30s, think EBITA maybe 20%, where Teledyne as a whole, even with corporate costs in Q2 and gross margins are at low 40s. So a little bit less because exotics high billing material. So gross margin is a little bit lower. But then SG&A shouldn't be as high as it is. You've got a handful of key accounts in both the security inspection and in the medical imaging domain. And so I think we can be a little bit leaner then. And of course, public company costs go out and things like that. So I do think it will be probably mid- to high teens soon, soon being public company costs and others 12 to 18 months. I think it will probably take maybe 2 to 3 years to get to the 20. It will be a little bit of a harder work, if you will, but there's definitely a good path. .
Adam Samuelson
analystOkay. That's helpful. And maybe just maybe to close out on the M&A front. I mean balance sheet is in great shape even after Varex, so I mean your pro leverage is going to be low 1, 1.2, low 1.1, 1.3, somewhere in that range. Just help us think about kind of the continued appetite for M&A, the capacity internally to do more deals and especially where mean these aren't smaller -- these aren't very small tuck-ins anymore with $1 billion I'm not saying they're informative, but they're not small. So how do you think about the management capacity to start taking on kind of chunkier acquisitions going forward?
Jason VanWees
executiveYes. Well both management capacity as well as balance sheet capacity. So really shouldn't be an issue we've done 75, Varex pending is 76. So what typically we haven't done is when we do another health care acquisition immediately after Varex. We'll know because I'd say we want the person who runs that business to be focused on that business. being tucked into a Teledyne company. It's a complementary business and a market that we're already in. We probably won't do one of those immediately. But that leaves another 80% of the portfolio that we just talked about that is not taxed at the management level, and we certainly have the corporate bandwidth and we certainly have the balance sheet. That said, we're price disciplined. I mean we've looked at a lot of aerospace and space acquisitions in the last 2 years. Most of those we've been out there on most of those haven't closed or been announced that we'll see what happens if time changes. But we tend to be price disciplined. I mean, we're not -- we win auctions. We're not a bottom fisher but we're not going to also do anything silly. Pay high teens, 20-plus EBITDA. I don't think that's wise. But we'll do those, keep looking for acquisitions. We're not at the law of large numbers yet. So I think there's plenty of targets of opportunity to keep going even beyond this. But on the other hand, we're opportunistic with share repurchases as well. We don't have an ongoing plan to buy back stock. We don't have a comment that we're going to buy so many shares per year to limit option creep or things like that. But we are relatively aggressive in after April 2024 when our stocks sold off without unfairly we were quite aggressive in Q4 2025 when we think our stock sold off unnecessarily. And that may be the case now that we've gone from $690 million to sub-600 -- it's a tool and a tool kit. We don't say what we're doing, but we have the language in our K that we have more than $1 billion still authorized and don't be surprised if we may do some of that here in the fading days of the quarter as well.
Adam Samuelson
analystOkay. That's very helpful. Maybe pivoting kind of more holistically on the margin side. I mean, second quarter kind of was a bit of a high watermark, maybe some extra benefits because tariff benefits that you kind of realized from refunds. But business as a whole growing kind of mid-single digit organically. Help us think about kind of the operating leverage and kind of how that should translate to both margin expansion and kind of what the ceiling you think can be for margins for the company?
Jason VanWees
executiveYes. I mean just to reiterate, so digital imaging in part because of the organic growth of the 11.9% in Q2, but in part because of the tariff refunds, I mean, yes, the margins were up in that segment, which is our largest, about 250 basis points. But in fairness, about half of that was tariff refunds. And the total company was about 120 basis points in Q2, though that tariff refunds were probably 60 of that or something of that nature. So still a good margin improvement really across the company, a couple of exceptions to that. But where there were sections, it was because we're there was some tangible mixed negative things, like unmanned subsea vehicles have lower margin than subsea sensors and unmanned subsea vehicles grew a lot in Q1 and Q2. So the margins were lower, again, so key for sales, okay, for EBIT, but if you're selling some of the systems have lower gross margins. by their nature than just sensor content. In terms of operating leverage, as you saw it in Q2, we're expecting this year about 60 basis points to the total company level. Digital Imaging will be north of 100, even excluding tariffs because it has the highest growth. In all honesty, though, we're actually having a little bit of mix negative. Now again, we're growing fast enough that we're still getting margin improvement. But generally speaking, and not by a big margin, but all things defense are a little bit lower margin than all things commercial and defense is growing faster than commercial. Now they're all doing well. I said defense this year might be double digits and the commercial stuff may be mid-single kind of at worst. But that said, that's actually a little bit mix negative. Again, get enough operating leverage to offset that you still got margin improvement. But there, we've actually been probably a negative mix the last sort of 6 quarters or so against the still receive margin improvement on the operating leverage and growth, but borderline a little bit of mix negative behind the scenes.
Adam Samuelson
analystYes. Well, I mean the way you framed the growth outlook earlier would seem like that mix kind of headwind is going to persist, if all else equal, some of the opportunities that are ahead on the deficit. So how do we think about kind of the ability for productivity, pricing initiatives to balance that?
Jason VanWees
executiveI think it will balance. I mean it has balanced. It's just -- I'm trying to keep people's expectations on operating leverage a little bit more reasonable because the things that are growing the fastest still very profitable, but just marginally less profitable and say something like semiconductor wafer inspection has higher contribution margin than, say, something like an unmanned subsea vehicles. not shouldn't be a surprise. And some of that is turning around and that's what we saw in Q2 was that some of the things that have been slower growth on the commercial and industrial side were mid- to high single or even in some wedges like, again, semiconductor wafer infection, we're in the doubles as well. That said, on pricing. I mean, yes, in fairness, there was probably 3 points of price in the 9% organic in Q2 because in certain areas you needed it, and we're niche enough that you can get. But you needed it, where you have -- we're not a huge consumer of memory, and they're going to talk about that. But we do buy some memory ironically, in some of those products that go to memory makers for semiconductor. And so price of the components is higher the part of our product is higher. Certain people have talked about rare or so germanium or things like that. And yes, there has been price inflation. Nothing so far is constricted supply or constricted our shipments yet, but it has been an inflationary annoyance like Xilinx FPGA is circa 2022. And we had probably $100 million of cost creep in 2022 for electronic components. And one of the reasons we had high single-digit organic growth was we had to probably put in 3, 4 points to price circa 2022. So we'll do that as necessary to come that inflation.
Adam Samuelson
analystGot it. And so I mean you just called out some supply chain and annoyances. Is there anything kind of that has maybe become doubling up beyond the annoyance phase at this point on the supply chain and raw material or cost inflation broadly? Or is it still in the management world?
Jason VanWees
executiveIt's certainly tangible. I mean it's been mostly an annoyance with regard to inflation and with an annoyance with regard to constraint of supply or constraint of shipment. I mean, again, the organic growth is pretty good at 9% in some of the businesses like defense that consume some of the more exotic stuff grew double digits in Q2. So it certainly has not been yet. It could be. I mean it's a risk factor in our 10-K. I mean, it should be -- I think everybody has it. But right now, it's been more of an inflation that we've priced in than a limit shipment -- limit of shipments, for example. .
Adam Samuelson
analystOkay. So I mean, I think we talked about and the company has been growing inorganically over time. Is there any thought or how do you think about divestitures as part of that capital allocation to okay? Is there any part of times you see parts of the portfolio that maybe this isn't there for anymore, maybe the competitive set, the customer set isn't kind of where it had been originally and it may not be a televisit.
Jason VanWees
executiveYes. Not now. I mean we've interesting, we've actually ever sold anything that we've acquired. So it's not a private equity model. We try to seek a permanent home for businesses that we buy. Now again, there's a little bit of 80/20 in product protein one of the reasons why doing fantastic organically now, but one of the reasons why revenue was kind of flattish at FLIR that we won in 2021 for the first couple of years is there's probably about $130 million of the $2 billion of revenue that was not good revenue. And that's probably not divestible products. They weren't businesses. They were products that they were losing money on every unit. So those just went away, and that was okay. But again, it did make FLIR look a little bit flattish for a couple of years. So there's 80/20 pruning. We're not -- especially when we business, we're not married to every single product line. Sometimes people my personal opinion, this may even BS when you run a business, nobody wants to contract, right? You want to grow, but then some of you get married to products that you probably shouldn't be doing where you were a little bit more dispassionate when you buy a business. And so -- there's been some 80/20 pruning. But that said, we have made a number of divestitures. I mean, since I joined, we probably if you go to originate, which was closer to $600 million, $700 million, circa 1999, 1/3 of that doesn't exist. 1/3 to $700 million today, $6.5 billion doesn't seem like a lot, but 1/3 of the company that we had is we divested over the years. So we've kind of finished with that process. what we have is what we like. But again, there's always a little bit of pruning here and there. If a product line doesn't make sense, especially when you do an acquisition.
Adam Samuelson
analystOkay. Great. Well, I think we're just about up at time. So Jason, I want to thank you and thank everyone for joining us today.
Jason VanWees
executiveThanks everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teledyne Technologies Incorporated transcript — plus 256,000+ transcripts from 12,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teledyne Technologies Incorporated earnings transcripts and 256,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teledyne Technologies Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.